Leerink Partnrs Analysts Boost Earnings Estimates for Hims & Hers Health, Inc. (NYSE:HIMS)

Hims & Hers Health, Inc. (NYSE:HIMS) – Equities research analysts at Leerink Partnrs boosted their Q2 2024 earnings per share (EPS) estimates for Hims & Hers Health in a research note issued to investors on Tuesday, May 7th. Leerink Partnrs analyst M. Cherny now anticipates that the company will earn $0.05 per share for the quarter, up from their previous forecast of $0.02. Leerink Partnrs currently has a “Market Perform” rating on the stock. The consensus estimate for Hims & Hers Health’s current full-year earnings is $0.11 per share. Leerink Partnrs also issued estimates for Hims & Hers Health’s Q3 2024 earnings at $0.05 EPS, FY2024 earnings at $0.18 EPS, FY2025 earnings at $0.29 EPS, FY2026 earnings at $0.45 EPS and FY2027 earnings at $0.67 EPS.

HIMS has been the subject of a number of other reports. Imperial Capital upgraded shares of Hims & Hers Health from an “in-line” rating to an “outperform” rating and set a $16.00 price target for the company in a report on Wednesday, February 28th. Seaport Res Ptn restated a “buy” rating on shares of Hims & Hers Health in a report on Friday, April 26th. Citigroup lifted their price target on Hims & Hers Health from $12.00 to $16.00 and gave the company a “buy” rating in a research note on Tuesday, February 27th. Canaccord Genuity Group initiated coverage on Hims & Hers Health in a report on Wednesday, April 10th. They issued a “buy” rating and a $20.00 target price on the stock. Finally, Piper Sandler lifted their target price on Hims & Hers Health from $11.00 to $13.00 and gave the company a “neutral” rating in a research report on Tuesday. Six equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Hims & Hers Health currently has an average rating of “Moderate Buy” and a consensus target price of $15.07.

Hims & Hers Health Price Performance

Shares of NYSE:HIMS opened at $12.16 on Thursday. Hims & Hers Health has a 1 year low of $5.65 and a 1 year high of $17.16. The business’s 50-day moving average is $14.01 and its 200-day moving average is $10.39. The company has a market capitalization of $2.61 billion, a price-to-earnings ratio of -107.91 and a beta of 0.97.

Hims & Hers Health (NYSE:HIMS) last released its earnings results on Monday, May 6th. The company reported $0.05 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.02 by $0.03. The business had revenue of $278.20 million for the quarter, compared to analyst estimates of $270.37 million. Hims & Hers Health had a negative net margin of 2.70% and a negative return on equity of 7.21%. Hims & Hers Health’s revenue for the quarter was up 45.8% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.05) earnings per share.

Insider Activity

In other news, insider Soleil Boughton sold 4,080 shares of the firm’s stock in a transaction on Friday, February 9th. The stock was sold at an average price of $10.03, for a total value of $40,922.40. Following the completion of the transaction, the insider now directly owns 154,345 shares of the company’s stock, valued at $1,548,080.35. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, insider Soleil Boughton sold 4,080 shares of the stock in a transaction dated Friday, February 9th. The shares were sold at an average price of $10.03, for a total value of $40,922.40. Following the sale, the insider now directly owns 154,345 shares of the company’s stock, valued at $1,548,080.35. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Andrew Dudum sold 97,208 shares of the business’s stock in a transaction that occurred on Tuesday, February 13th. The shares were sold at an average price of $9.58, for a total transaction of $931,252.64. Following the transaction, the chief executive officer now directly owns 51,653 shares of the company’s stock, valued at approximately $494,835.74. The disclosure for this sale can be found here. Insiders have sold a total of 736,191 shares of company stock valued at $9,733,700 over the last quarter. Company insiders own 31.63% of the company’s stock.

Hedge Funds Weigh In On Hims & Hers Health

Institutional investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. increased its position in shares of Hims & Hers Health by 0.3% in the fourth quarter. Vanguard Group Inc. now owns 14,173,285 shares of the company’s stock worth $126,142,000 after purchasing an additional 46,541 shares during the last quarter. Forerunner Ventures Management LLC bought a new position in Hims & Hers Health in the 4th quarter worth approximately $86,836,000. Dimensional Fund Advisors LP raised its position in Hims & Hers Health by 9.9% during the fourth quarter. Dimensional Fund Advisors LP now owns 2,147,927 shares of the company’s stock valued at $19,117,000 after purchasing an additional 193,507 shares during the period. Charles Schwab Investment Management Inc. increased its position in shares of Hims & Hers Health by 1.7% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,294,759 shares of the company’s stock valued at $11,523,000 after purchasing an additional 22,009 shares during the last quarter. Finally, Federated Hermes Inc. increased its position in Hims & Hers Health by 38.6% during the third quarter. Federated Hermes Inc. now owns 1,032,452 shares of the company’s stock valued at $6,494,000 after acquiring an additional 287,552 shares during the last quarter. 63.52% of the stock is currently owned by institutional investors.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.